Executive summary

Based on the study report dated 23 June 2021, Effect of Broth & Co’s Beef Bone Broth on Lower Gastrointestinal Disturbances.

Broth & Co Beef Bone Broth Powder was evaluated in a 12-week, single-arm interventional study involving Australian adults with moderate lower gastrointestinal symptoms. After a 3–4 week run-in period, participants consumed 5 g of freeze-dried beef bone broth powder twice daily for 8 weeks.

The study assessed gastrointestinal symptoms, stool form and frequency, symptom-related quality of life, abdominal pain, reported food triggers and intestinal permeability.

Following the 8-week intervention, statistically significant improvements were reported across several lower gastrointestinal measures, including constipation-related symptoms, loose stools, urgency, abdominal pain and troublesome flatulence. The overall Birmingham IBS symptom score improved significantly (p < 0.0001).

Upper gastrointestinal symptoms also improved, including indigestion, heartburn and regurgitation, together with a significant improvement in the total Leeds questionnaire score. Stool patterns shifted towards the ideal Bristol Stool Form Scale Type 4 profile, while total IBS-related quality-of-life scores improved significantly (p < 0.001).

Among participants with elevated intestinal permeability markers at baseline, lactulose recovery improved by 33% (p = 0.023) and mannitol recovery improved by 33% (p = 0.006). A 38% change was also observed in the subgroup with an elevated lactulose-to-mannitol ratio. However, this subgroup was small (n = 6) and the change was not statistically significant.

These findings provide encouraging evidence supporting the role of Broth & Co Beef Bone Broth Powder in digestive health and gut barrier function. As with all emerging clinical research, further studies will help build on these findings and continue to expand the evidence base.